Last updated on January 2017

A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: *Healthy Children Studies
  • Age: Between 18 - 74 Years
  • Gender: Male or Female

Migraines for at least a year

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.